SOHO 2023 | Approaching ESA failure in patients with lower-risk MDS
Valeria Santini
• 7 Sep 2023
Valeria Santini, MD, University of Florence, Florence, Italy, comments on factors that influence patient response to erythropoietin stimulating agents (ESAs), and further discusses how to approach ESA failure in patients with lower-risk myelodysplastic syndromes (LR-MDS). Prof. Santini highlights the importance of enrolling patients in clinical trials and further discusses the role of novel agents such as luspatercept. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
